---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/37385037.md"
description: "$Novo Nordisk AS(NVO.US) is hopeless. The world's first oral weight-loss drug was approved, but the stock only rose a little, which shows how little the market thinks of Novo Nordisk. If it drags on until March-June 2026 when Eli Lilly's oral weight-loss drug is approved, NVO will be completely finished."
datetime: "2025-12-26T15:07:14.000Z"
locales:
  - [en](https://longbridge.com/en/topics/37385037.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/37385037.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/37385037.md)
author: "[爱吃羊肉的耗子](https://longbridge.com/en/profiles/12201248.md)"
---

# $Novo Nordisk AS(NVO.US) is hopeless. The world's …


### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

## Comments (5)

- **爱吃羊肉的耗子 · 2025-12-26T15:10:11.000Z**: Cheap? That's because the industry has been completely reshuffled, Novo's core advantages have been replaced. What's the use of being cheap? The current stock price is the reasonable value now, and you still think it can double and break the previous high?
  - **张斐骑牛** (2025-12-26T15:34:30.000Z): Need to see sales growth
  - **爱吃羊肉的耗子** (2025-12-26T15:42:13.000Z): Growth is difficult. Eli Lilly's tirzepatide now has a huge advantage, whether in terms of price or efficacy, completely crushing Novo Nordisk. Moreover, when Lilly's oral drug comes out next year, it
  - **太夸张了你** (2025-12-27T00:15:12.000Z): More words don't mean you're right. I don't agree with what you said.